Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

NCT03971643 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Pyoderma Gangrenosum

Interventions

DRUG: vilobelimab

Sponsor

InflaRx GmbH

Collaborators

[object Object]